SIX CO-LOCATED PROGRAMMES ACROSS ASIA’S BIOPHARMA VALUE CHAIN

23 - 24 March 2027 Sands Expo & Convention Centre, Singapore
The Six Programmes
BMA 2027 White Visit Brochure
ADC 2027 White Visit Brochure
CGTWA 2027 White Visit Brochure
CTFA 2027 White Visit Brochure
OPWA 2027 White Visit Brochure
BSCA 2027 White Visit Brochure
Awards

About the Event

Biopharma APAC Confex 2027 brings six co-located conferences under one roof at the Sands Expo & Convention Centre, Singapore, on 23–24 March 2027: Biologics Manufacturing Asia, ADC Asia Congress, Cell & Gene Therapy World Asia, Clinical Trials Festival Asia, Oligos & Peptides World Asia and Biosupply Chain Asia. One registration, one exhibition floor, and one decision-making community across the modalities reshaping the region’s biopharma pipeline.

Each programme runs its own two-day agenda, so delegates can go deep in their own field and still move freely between the others — the conversations between the programmes are the point of co-locating them. Together the six agendas span process development and biomanufacturing, antibody–drug conjugates, cell and gene therapies, clinical trial design and execution, oligonucleotide and peptide therapeutics, and the supply chain that carries all of them to patients.

What we'll cover

Key Themes

Biologics Manufacturing
Upstream and downstream process development, CMC, analytics and characterisation, formulation, facility engineering and digital manufacturing — from robust cell lines to real-time release.
Antibody–Drug Conjugates
Discovery and next-generation targeting, pre-clinical translation, formulation and stability, and the safety–efficacy balance that decides whether an ADC reaches patients.
Cell & Gene Therapy
CAR-T, gene editing and emerging modalities; vector engineering, delivery and analytics; scale-up, tech transfer and CMC readiness; and the regulatory and market-access routes to commercialisation.
Clinical Trials
APAC trial harmonisation and emerging markets, patient-centric and decentralised designs, digital endpoints and wearables, AI in trial execution, and the logistics behind a multi-country study.
Oligos & Peptides
The RNA and oligonucleotide landscape in APAC, peptide therapeutics, delivery technologies and precision tissue targeting, and manufacturing, CMC and commercial scale-up.
Biopharma Supply Chain
Resilient and future-ready cold chain, next-generation logistics, smart packaging and traceability, sustainability in cold and ambient chains, and GxP compliance across Asian markets.
BY THE NUMBERS

Our Impact in Asia's Biopharma

2000+
Attendees
700+
Companies
250+
Speakers

Testimonials

Hear from past attendees and industry leaders

“The conference provides a forum for latest sharing and networking among biopharma peers from different organisations. The panel discussions are particularly informative as they cover realistic, contemporaneous and first-hand sharing on opportunities and challenges facing the industry and organisations. One key highlight of the conference is the ABEA Night. This prestigious recognition highlights the outstanding contributions of individual leader advancing biopharma excellence in the Asia-Pacific region.”
Vice President & Site Quality Head, Global Quality
Takeda
Singapore flag Singapore
“It was a very valuable conference experience. I was pleased to have the opportunity to present and discuss our technology with peers in the field, which led to several new and meaningful engagements. The meeting also offered a strong scientific programme, and it was inspiring to hear high-quality work from other groups. Beyond the content itself, the conference was especially useful for building new connections and opening the door to potential future collaborations.”
CTO
Singzyme
Singapore flag Singapore
“Thank you so much for organizing such a well-run event. It was truly a pleasure to contribute, and I enjoyed the atmosphere and engagement from the audience during the event.”
Corporate Performance Specialist
Biofarma
Indonesia flag Indonesia
“Overall, we believe the event was very well organized and successful. From an exhibitor’s perspective, the arrangement of 1-to-1 meetings was particularly useful and added significant value.”
Business Development Director
Pfanstiehl
Singapore flag Singapore
"Insights from industry leaders are valuable and cannot be found easily online"
Technical Steward
BioNTech
Singapore flag Singapore
“Thanks for organizing BioSupply Chain Asia, it was a good event and I have learnt a lot.”
Head of Singapore Explore Platform
Sanofi
Singapore flag Singapore
“The team was very friendly and helpful. They were committed to scheduling 1-to-1 meetings and ensuring it went smoothly.”
BDM
SGS
Singapore flag Singapore
“Good team, clever techniques to bring people in contact. Appreciate their effort and help.”
Product & Sales Manager
DrM Group
Switzerland flag Switzerland

Partners 2027

Confirmed partners across all six Biopharma APAC Confex 2027 programmes

Platinum Sponsor
cytiva-logo-vector
Gold Sponsors
Becton_Dickinson_logo.svg
WuXi Biologics
Silver Sponsors
Pfanstiehl-hd
Sartorius Logo
BSP logo 1
Bronze Sponsors
Wuxi XDC_logo_4C
Nona-logo-vertical color 1
Associate Sponsors
Uniqculture
Networking Partner
Almac Group
Exhibitors
DYE logo blue 1
Duoning-Logo-EN-small-1
DrM_Logo
PharmNXT Logo_COLOUR_transparent 2K
Single Use Support
Tosoh Bioscience
Truking logo 1
Hycure
Merck
avantor-inc-logo-vector
Meissner Corporation
Aber
Ami Polymer
ORKA Pharma-navyblue transparent
Infors HT
3CON-Logo_Life_Subtitle_Aqua-Grey
IMG_5072
Catalent-Pharma Services-TM-Logo-Color-RGB 2
Honya Biotech 1
Qickstat
Media & Publicity
Life Sciences Review
BioPharma Asia Logo
Cell & Gene
Nucleic Acid Insights

Agenda at a Glance

CONFERENCE DAY 1 | Tuesday, 23 March 2027
Biologics Manufacturing Asia 2027 ADC Asia Congress 2027 Cell & Gene Therapy World Asia 2027 Clinical Trials Festival Asia 2027 Oligos & Peptides World Asia 2027 Biosupply Chain Asia 2027
Track 1Track 2
Building Asia’s Global Leadership in Biologics, ADCs & Novel Modalities
Leadership Panel Discussion
Next-Generation Cell & Gene Therapies
APAC Trial Harmonization & Emerging Markets
RNA & Oligonucleotides Landscape in APAC
Building Resilient Cold Chain & Future-Ready Biopharma Supply Chains in Asia
Morning Break, Exhibition Viewing & 1-1 Networking
Upstream Processing
Downstream Processing
Discovery
From Discovery to Clinical Translation
Navigating the Future of Patient-Centric Trials
Peptide Therapeutics 2.0
Next-Gen Cold Chain Logistics
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Upstream Processing
Analytics & Characterization
Advancing Pre-Clinical Research
Gene & Cell Therapy Platforms
Advancing Pre-Clinical Research Bringing the Gap
Delivery Technologies & Precision Tissue Targeting
Driving Sustainability in Cold and Ambient Chain Logistics
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Downstream Processing
MSAT & Tech Transfer Excellence
Formulation & Stability
Smart Manufacturing & Process Development for CGTs
Decentralized Trials, Digital Endpoints, and Wearables
Oligonucleotide-Peptide Conjugates & Novel Modalities
Smart Packaging & Traceability for Temperature-Sensitive Biologics
End of Conference Day 1
CONFERENCE DAY 2 | Wednesday, 24 March 2027
Biologics Manufacturing Asia 2027 ADC Asia Congress 2027 Cell & Gene Therapy World Asia 2027 Clinical Trials Festival Asia 2027 Oligos & Peptides World Asia 2027 Biosupply Chain Asia 2027
Track 1Track 2
CMC, Analytics & Quality Achieving CMC Excellence, Integrated Analytics, Quality Control & Regulatory Readiness
Leadership Panel Discussion
Advanced Cell Therapies
AI & Digital Transformation in Trial Execution
Clinical Development & Regulatory Excellence
Smart Supply Chain 4.0
Morning Break, Exhibition Viewing & 1-1 Networking
Formulation, Development & Manufacturing
Smart, Agile and Digital Manufacturing
Safety and Efficacy
Manufacturing Excellence
Transforming Clinical Trial Logistics in APAC
Manufacturing, CMC & Commercial Scale-Up
Transforming Clinical Trial Logistics in APAC
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Process Analytics & Real-Time Manufacturing
Facility Engineering & Infrastructure Excellence
ADC Biopharma Showcase
Supply Chain & Operational Excellence for CGTs
APAC CRO Showcase
Quality, Analytics & Regulatory Innovation
Meeting Regulatory Expectations & GxP Compliance in Asia
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Closing Roundtable Discussion
Regulatory Pathways, Market Access & Commercialization
Closing Panel Discussion
Convergence of RNA, Peptides & Next-Generation Therapeutics
Future-Proofing Biopharma Supply Chains in Asia 2027-2030
End of Conference Day 2
FULL AGENDA

Choose a programme

BIOLOGICS MANUFACTURING ASIA 2027

Day 1

Tuesday, 23 March 2027

Track 1
Track 2
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
TRACK
Building Asia’s Global Leadership in Biologics, ADCs & Novel Modalities
9:00
Leadership Panel Discussion: Asia’s Biologics Ambition: From Regional Manufacturing Hub to Global Innovation Powerhouse
  • Evaluating Asia’s competitive advantage in biologics development, manufacturing, and commercialization.
  • Identifying critical investments required in talent, infrastructure, and technology to compete globally.
  • Strengthening regional collaboration between governments, industry, academia, and investors.
  • Building resilient and future-ready biologics ecosystems capable of supporting next-generation therapeutics.
PANELISTS
Teck Chung Chang
Teck Chung Chang
VP, Site Quality Head, Takeda
9:50
Accelerating Development Timelines: Innovative Technologies for Biologics, ADCs & Emerging Modalities
  • Showcasing next-generation technologies enabling faster process development and optimization.
  • Exploring advanced analytical tools for improving product characterization and quality control.
  • Examining innovations in conjugation, formulation, and delivery technologies for ADCs and novel therapeutics.
  • Discussing how technology providers and CDMOs can support rapid clinical and commercial manufacturing.
Reserved for Solution Providers
10:05
Advancing Biologics Development: Enhancing Speed, Quality and Commercial Readiness
  • Implementing platform-based approaches to accelerate biologics development timelines.
  • Improving cell line development, process development, and analytical characterization strategies.
  • Managing technology transfer and global manufacturing network expansion.
  • Balancing innovation, cost-efficiency, and regulatory compliance throughout product development.
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Upstream Processing — Robust Cell Lines & Optimized Expression Systems
TRACK
Downstream Processing — Advancing Final Product Quality: Polishing, Viral Clearance & Formulation
11:15
Engineering Next-Generation Cell Lines for High Productivity, Stability & Product Quality
  • Balancing productivity, genetic stability, and critical quality attributes (CQAs) during cell line development.
  • Leveraging CRISPR, targeted integration, and host cell engineering to create robust production cell lines.
  • Strategies to address difficult-to-express proteins, bispecific antibodies, and novel biologic modalities.
  • Accelerating clone selection and characterization while maintaining regulatory compliance and manufacturability
11:15
Doing More with Less: Reducing Buffers, Water, Resin and Waste in Downstream Processing
  • Addressing the growing buffer and water footprint of large-scale biologics purification.
  • Exploring buffer concentrates, inline conditioning and alternative chromatography approaches.
  • Extending resin lifetime while maintaining cleaning effectiveness and product quality.
  • Connecting DSP sustainability improvements with manufacturing cost and facility capacity objectives.
11:40
AI, Automation & Digital Cell Line Development: Accelerating the Path to High-Producing Clones
  • How AI and machine learning are transforming clone selection, cell line screening, and process optimization.
  • Digital platforms, automated single-cell cloning, and high-throughput technologies enabling faster development cycles.
  • Using predictive analytics to improve manufacturability, productivity, and product quality outcomes.
  • Case studies demonstrating reduced timelines and increased success rates through digitalized cell line development
Reserved for Solution Providers
11:40
Polishing Under Pressure: Removing HCPs, Aggregates and Process-Related Impurities at Higher Titres
  • Designing robust polishing strategies for increasingly concentrated and complex feed streams.
  • Tackling difficult-to-remove host cell proteins, DNA, aggregates and leachables.
  • Optimising resin selection, loading capacity and operating conditions to reduce purification cycles.
  • Applying advanced analytics to understand impurity behaviour and strengthen clearance validation
Reserved for Solution Providers
11:55
Enhancing Upstream Productivity Through Advanced Media and Feed Optimization
  • Designing chemically defined media for improved cell performance.
  • Optimizing feeding strategies to maximize yield and viability.
  • Leveraging metabolomics for media development.
  • Real-world examples of process intensification through media optimization.
11:55
Formulation at Higher Concentrations: Solving Stability, Viscosity and Aggregation Challenges
  • Developing high-concentration formulations for subcutaneous and patient-friendly delivery.
  • Managing viscosity, aggregation, particle formation and protein–protein interactions.
  • Optimising excipient selection and formulation conditions to preserve long-term stability.
  • Integrating formulation development earlier with upstream and downstream process development.
12:20
Lunch – Exhibition Viewing & 1-1 Networking
TRACK
Upstream Processing: Process Intensification Strategies: Perfusion, Fed-Batch & High- Density Strategies
TRACK
Analytics & Characterization: Next-Generation Methods for Product Quality & Process Excellence
2:05
Beyond Titre: Redefining Upstream Productivity Through High-Density Process Intensification
  • Benchmark perfusion, intensified fed-batch and conventional fed-batch across titre, volumetric productivity and facility throughput.
  • Optimise cell-specific productivity, viable cell density and culture longevity without compromising CQAs.
  • Manage oxygen transfer, CO₂ accumulation, osmolality and nutrient limitations at ultra-high cell densities.
  • Determine when higher upstream productivity translates into lower COGS and smaller manufacturing footprints.
2:05
Multi-Attribute Methods 2.0: Moving MAM from Characterization into Routine QC and Product Release
  • Expanding LC-MS-based MAM from development laboratories toward QC environments for simultaneous monitoring of multiple product quality attributes.
  • Tackling method robustness, validation, data processing and comparability challenges associated with routine MAM implementation.
  • Evaluating how MAM can complement or replace conventional analytical assays without increasing regulatory risk.
  • Building regulatory confidence and harmonised implementation strategies across differing APAC market requirements.
2:30
Intensified Fed-Batch 2.0: Pushing Cell Density Without Pushing Process Risk
  • Design high-density seed trains and N-1 perfusion strategies to shorten production bioreactor occupancy.
  • Optimise inoculation density, feeding profiles and metabolic control for accelerated production cycles.
  • Prevent lactate, ammonia and other inhibitory metabolite accumulation at elevated biomass levels.
  • Evaluate the productivity-versus-complexity trade-off compared with full perfusion.
Reserved for Solution Provider
2:30
AI-Enabled Analytical Development: From Data-Rich Experiments to Faster Quality Decisions
  • Applying AI/ML to analytical method development, optimization, and interpretation of complex datasets.
  • Connecting PAT, process, and laboratory data to identify emerging quality trends.
  • Using predictive analytics to anticipate deviations, OOS/OOT results, and process drift.
  • Addressing model validation, data integrity, explainability, and regulatory acceptance across APAC
Reserved for Solution Provider
2:45
Intensification Without Compromise: Controlling CQAs in High-Density and Continuous Cultures
  • Understand how prolonged culture duration and altered cellular metabolism influence glycosylation, charge variants and aggregation.
  • Define CPP–CQA relationships specifically for perfusion and high-density processes.
  • Establish comparability strategies when transitioning commercial molecules from conventional fed-batch to intensified platforms.
  • Build control strategies that satisfy evolving expectations for continuous and intensified biomanufacturing in APAC.
2:45
Next-Generation Impurity Analytics: Detecting the Unknowns Before They Become a Quality Risk
  • Advancing detection and quantification of host-cell proteins, residual DNA, aggregates, fragments, process-related impurities and product variants.
  • Applying high-resolution MS, NGS and orthogonal analytical technologies to detect low-abundance and previously unidentified impurities.
  • Connecting impurity profiles with upstream and downstream process parameters to improve root-cause analysis and clearance strategies.
  • Developing risk-based impurity control strategies that remain robust through process changes, scale-up and technology transfer.
3:10
Breaking the Density Barrier: Engineering Robust High-Cell-Density Cultures at Commercial Scale
  • Optimising cell-line performance, media composition, feeding strategies, and process parameters at ultra-high cell densities.
  • Addressing oxygen transfer, CO₂ accumulation, osmolality, metabolite build-up, and mixing limitations as density increases.
  • Understanding how intensified culture conditions influence CQAs, glycosylation, aggregation, and product consistency.
  • Translating high-density performance from development-scale bioreactors into reliable GMP manufacturing.
Reserved for Solution Provider
3:10
Beyond Manual Testing: Accelerating Quality Decisions Through Automated Analytics
  • Advancing automated sample preparation, testing and data analysis to improve throughput, reproducibility and right-first-time results.
  • Integrating robotics, miniaturised assays and high-throughput analytical platforms to accelerate testing across development and commercial manufacturing.
  • Connecting laboratory automation with LIMS, ELN and manufacturing systems to enable seamless data flow and faster quality decisions.
  • Overcoming APAC implementation barriers around validation, legacy-system integration, workforce readiness and investment justification.
Reserved for Solution Provider
3:25
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Downstream Processing — Refining Primary Recovery: Product Capture, Impurity Removal & Novel Methods
TRACK
MSAT & Tech Transfer Excellence: Scale-Up, Validation & Lifecycle Management
4:10
Capture Chromatography Under Pressure: Extending Resin Lifetime Without Compromising Product Quality
  • Optimising Protein A loading, cycling and resin utilisation as titres continue to increase.
  • Controlling resin fouling, ligand leaching and performance deterioration over extended campaigns.
  • Evaluating high-capacity resins, membranes and alternative affinity technologies to reduce capture bottlenecks.
  • Building resin lifecycle and cleaning strategies suited to APAC's growing multi-product manufacturing environment.
4:10
Raw Materials Under Control: Managing Variability During Scale-Up, Transfer & Commercial Manufacturing
  • Identifying raw-material attributes with the greatest impact on process performance and product quality
  • Managing supplier, lot-to-lot and regional sourcing variability during site transfers
  • Developing material qualification and risk-ranking strategies based on process understanding
  • Using MSAT and manufacturing data to establish relationships between material variability and CQAs
4:35
Smarter Impurity Clearance: Tackling HCP, DNA, Aggregates & Process-Related Contaminants
  • Understanding how intensified upstream processes change host-cell protein and impurity profiles.
  • Improving removal of HCP, residual DNA, aggregates, leachables and other process-related impurities.
  • Applying orthogonal purification strategies to address difficult-to-remove contaminants.
  • Using enhanced analytics to understand impurity trajectories and optimise downstream unit operations.
Reserved for Solution Provider
4:35
From Development to Commercial Scale: De-Risking Biologics Scale-Up Without Losing Process Performance
  • Translating small-scale process understanding into robust commercial-scale operating ranges
  • Managing scale-dependent CPPs, mass transfer, mixing, shear and bioreactor geometry
  • Using engineering runs, scale-down models and risk assessments to predict scale-up failure
  • Building MSAT strategies that shorten the path from clinical manufacturing to PPQ
4:50
Continuous & Intensified Downstream Processing: Moving from Unit Operations to Integrated Purification
  • Integrating continuous chromatography, filtration and buffer management into connected downstream workflows.
  • Overcoming process-control and equipment-integration challenges associated with continuous manufacturing.
  • Using PAT and real-time monitoring to maintain critical quality attributes during intensified processing.
  • Determining where continuous downstream processing delivers meaningful productivity and COGS advantages in APAC.
4:50
Managing Change Without Revalidating Everything: Smarter Lifecycle & Post-Approval Change Management
  • Applying science- and risk-based approaches to determine the validation impact of process changes
  • Leveraging established conditions and Post-Approval Change Management Protocols
  • Managing equipment, raw-material, scale and site changes without compromising the validated state
  • Navigating different APAC expectations for variations and post-approval CMC changes
5:15
Driving Down Cost of Goods: Maximising Downstream Productivity, Efficiency & Facility Utilisation
  • Optimising resin utilisation, buffer consumption and water demand while maintaining yield, purity and critical quality attributes.
  • Leveraging buffer concentrates, inline conditioning and inline dilution to reduce preparation burden, storage requirements and facility complexity.
  • Applying downstream process intensification to increase throughput and capacity within brownfield and space-constrained APAC manufacturing facilities.
  • Translating DSP improvements into measurable gains in cost per batch, cost per gram, facility utilisation and manufacturing capacity.
5:15
Tech Transfer Under Pressure: Achieving Right-First-Time Transfer Across APAC Manufacturing Networks
  • Identifying hidden gaps between sending-unit process knowledge and receiving-site capabilities
  • Assessing equipment, facility, raw-material and analytical differences before transfer execution
  • Establishing clear MSAT, process development, quality, engineering and manufacturing ownership
  • Developing readiness metrics and stage-gate models to reduce deviations and repeat engineering runs
5:40
Chairman’s Closing Remarks
5:45
End of day 1
6:00
Cocktails & Networking
6:30
Asia Pacific Biopharma Excellence Awards 2027 | Gala Dinner
BIOLOGICS MANUFACTURING ASIA 2027

Day 2

Wednesday, 24 March 2027

Track 1
Track 2
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
TRACK
CMC, Analytics & Quality Achieving CMC Excellence, Integrated Analytics, Quality Control & Regulatory Readiness (Combined Track 1 and Track 2)
9:00
Regulatory-Ready CMC: Designing Global Development Programs for FDA, EMA & APAC Expectations
  • Building CMC strategies that anticipate evolving requirements across FDA, EMA and key APAC regulators.
  • Aligning analytical validation, process validation, comparability and stability strategies for global submissions.
  • Managing post-approval changes, manufacturing changes and lifecycle comparability without disrupting supply.
  • Strengthening regulatory engagement and documentation to reduce CMC questions, review cycles and approval delays.
9:50
Platform Analytics: Leveraging Analytical Methods Across Products and Development Pipelines
  • Establishing platform analytical procedures that can be applied across related molecules, modalities, and product families while maintaining product-specific scientific rigor.
  • Streamlining method development, qualification, and validation by leveraging prior analytical knowledge and proven platform capabilities.
  • Designing robust bridging and method-transfer strategies across products, manufacturing sites, QC laboratories, and global testing networks.
  • Defining the scientific evidence, comparability data, and regulatory justification required to support the use of platform methods across multiple products.
Reserved for Solution Providers
10:05
Comparability Under Pressure: Managing CMC Change Across Scale-Up, Tech Transfer & Manufacturing Networks
  • Designing comparability strategies for process changes, scale-up, site transfers, and manufacturing expansion.
  • Determining when analytical comparability is sufficient and when additional non-clinical or clinical evidence may be required.
  • Using orthogonal and advanced characterization methods to demonstrate product consistency.
  • Building change management strategies that enable manufacturing flexibility without creating regulatory delays.
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Formulation, Development & Manufacturing: — Stability, Drug Product Design & Commercialization
TRACK
Smart, Agile and Digital Manufacturing — Flexible Facilities, Digital First Operations and Single Use System
11:15
From Molecule to Medicine: Designing Drug Products for Stability, Delivery & Manufacturability
  • Translating molecule characteristics into the right formulation and dosage-form strategy.
  • Balancing potency, concentration, viscosity, stability, and patient usability.
  • Applying QbD to identify critical quality attributes and formulation design space.
  • Avoiding late-stage redesign by integrating manufacturing requirements from the outset.
11:15
From Fixed to Flexible: Designing Multi-Product Facilities for Asia’s Changing Biologics Pipeline
  • Designing facilities that can rapidly switch between products, modalities, and batch sizes.
  • Balancing ballroom, modular, and traditional facility configurations for different manufacturing needs.
  • Minimising changeover time, cross-contamination risk, and production downtime in multi-product environments.
  • Building flexibility into utilities, equipment, automation, and process flows without overengineering capacity.
11:40
Freeze, Dry or Reformulate? Advancing Lyophilization & Alternative Stability Strategies
  • Determining when lyophilization offers advantages over liquid formulations.
  • Optimizing freezing, primary drying, secondary drying, and cycle development.
  • Applying modeling and PAT to improve lyophilization robustness and cycle efficiency.
  • Scaling lyophilization processes while maintaining critical quality attributes and product stability.
Reserved for Solution Providers
11:40
Single-Use at Scale: Solving Cost, Supply and Sustainability Constraints
  • Where single-use technologies deliver the strongest operational and economic advantages versus stainless steel.
  • Addressing extractables/leachables, integrity, standardisation, and supplier qualification challenges.
  • Reducing dependence on imported consumables through stronger regional supply networks and dual sourcing.
  • Tackling plastic waste and developing credible sustainability strategies for disposable manufacturing systems.
11:55
Formulation Under Pressure: Solving Stability Challenges Before They Derail Development
  • Identifying degradation pathways and critical stability risks earlier in development.
  • Tackling aggregation, oxidation, deamidation, hydrolysis, and other product-specific liabilities.
  • Using predictive stability models and accelerated studies to guide formulation decisions.
  • Building stability-indicating strategies that support longer shelf life and commercialization.
11:55
Plug, Play, Scale: Modular Manufacturing for Faster Capacity Deployment
  • Using modular and prefabricated manufacturing concepts to shorten facility design, construction, and qualification timelines.
  • Creating repeatable manufacturing modules that can be replicated across Asian markets.
  • Matching modular capacity with uncertain demand and increasingly diversified biologics pipelines.
  • Managing regulatory, validation, utility, and technology-transfer challenges when scaling modular facilities.
12:20
Lunch – Exhibition Viewing & 1-1 Networking
TRACK
Process Analytics & Real-Time Manufacturing: — PAT, Advanced Monitoring & Real-Time Release
TRACK
Facility Engineering & Infrastructure Excellence: Designing, Operating & Future-Proofing Next-Generation Biomanufacturing Facilities
2:05
From PAT to RTRT: Building the Roadmap to Real-Time Release in Biologics
  • Translating PAT data into defensible real-time release strategies for biologics.
  • Connecting CPPs, CQAs and in-process measurements to release decisions.
  • Validating PAT models and demonstrating continued model performance.
  • Regulatory and operational barriers to moving from conventional QC release to RTRT.
2:05
From Design to GMP Operations: De-Risking Commissioning, Qualification & Facility Start-Up
  • Integrating C&Q requirements from concept and detailed design stages
  • Risk-based commissioning and qualification of facilities and utilities
  • Improving handover between engineering, validation, quality and operations
  • Avoiding common start-up failures that delay GMP readiness and production
2:30
Soft Sensors & Virtual Measurements: Predicting What You Cannot Measure In-Line
  • Developing soft sensors for CQAs that cannot be directly measured continuously.
  • Combining process data, mechanistic models and multivariate analytics.
  • Model calibration, validation and lifecycle management across batches and sites.
  • Using predictive signals for earlier deviation detection and proactive intervention.
Reserved for Solution Providers
2:30
Engineering the Cleanroom of the Future: Smarter HVAC, Zoning & Energy Optimization
  • Optimizing air-change rates without compromising GMP requirements
  • Risk-based cleanroom classification and HVAC zoning
  • Applying CFD and dynamic environmental control to facility design
  • Reducing HVAC energy consumption and lifecycle operating costs
2:45
PAT Across the Bioprocess: Connecting Upstream, Downstream & Product Quality
  • Deploying PAT from cell culture and harvest through chromatography and formulation
  • Monitoring CQAs and CPPs across interconnected unit operations
  • Connecting upstream variability with downstream purification performance
  • Building an integrated analytical control strategy instead of isolated PAT applications
2:45
Contamination Control by Design: Engineering Facilities for Annex 1 & PIC/S Readiness
  • Embedding contamination control strategy into facility layout and engineering design
  • Engineering pressure cascades, segregation and personnel/material flows
  • Integrating barrier technologies, environmental monitoring and closed processing
  • Designing facilities that maintain inspection readiness throughout their operational lifecycle
3:10
Digital Twins for Biologics: From Process Simulation to Real-Time Control
  • Developing hybrid digital twins using first-principles models and manufacturing data
  • Connecting PAT measurements to continuously update process-state estimates
  • Predicting deviations, yield and product-quality outcomes before they occur
  • Using digital twins for scale-up, process optimization, operator decision support and control
3:10
Capacity Without Overbuilding: Engineering the Right Facility for Asia's Next Biologics Pipeline
  • Using dynamic capacity modelling to determine facility size and configuration
  • Balancing current demand against uncertain future pipeline requirements
  • Deciding when to expand, retrofit, modularize or build greenfield capacity
  • Avoiding over-engineering while retaining sufficient flexibility for future products and technologies
3:35
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
4:20
Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
  • Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
  • Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
  • From Bench to Bedside: What’s Missing in Translating Preclinical ADC Wins to Clinical Success?
  • Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities
  • Navigating Investment in ADCs: Securing Funding for Innovation in Asia
  • Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
  • Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
  • Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
  • Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?
  • CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?
  • Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?
5:20
Chairman’s Closing Remarks
5:30
End of day 2
ADC ASIA CONGRESS 2027

Day 1

Tuesday, 23 March 2027

8:50
Chairman Opening Remarks
9:00
Leadership Panel Discussion: Asia’s Biologics Ambition: From Regional Manufacturing Hub to Global Innovation Powerhouse
  • Evaluating Asia’s competitive advantage in biologics development, manufacturing, and commercialization.
  • Identifying critical investments required in talent, infrastructure, and technology to compete globally.
  • Strengthening regional collaboration between governments, industry, academia, and investors.
  • Building resilient and future-ready biologics ecosystems capable of supporting next-generation therapeutics.
PANELISTS
Teck Chung Chang
Teck Chung Chang
VP, Site Quality Head, Takeda
9:25
Accelerating Development Timelines: Innovative Technologies for Biologics, ADCs & Emerging Modalities
  • Showcasing next-generation technologies enabling faster process development and optimization.
  • Exploring advanced analytical tools for improving product characterization and quality control.
  • Examining innovations in conjugation, formulation, and delivery technologies for ADCs and novel therapeutics.
  • Discussing how technology providers and CDMOs can support rapid clinical and commercial manufacturing.
Reserved for Solution Provider
9:50
Advancing Biologics Development: Enhancing Speed, Quality and Commercial Readiness
  • Implementing platform-based approaches to accelerate biologics development timelines.
  • Improving cell line development, process development, and analytical characterization strategies.
  • Managing technology transfer and global manufacturing network expansion.
  • Balancing innovation, cost-efficiency, and regulatory compliance throughout product development.
10:30
Morning Break – Exhibition Viewing & 1-1 Networking
11:15
Innovative Linker Strategies: Improving Stability and Tumor-Specific Activation
  • pH-sensitive and enzymatically cleavable linkers for targeted release
  • Strategies to minimize systemic toxicity and maximize drug release efficiency
  • Engineering linkers to overcome multi-drug resistance in tumors
11:40
Overcoming ADC Resistance: Strategies for Enhancing Tumor Cell Killing
  • Mechanisms of resistance: ADC efflux, antigen loss, and lysosomal degradation
  • Combination therapies: ADCs with checkpoint inhibitors and targeted therapies
  • Approaches to optimize ADC recycling and increase intracellular payload delivery
Reserved for Solution Provider
12:05
Targeted Immune-Stimulatory Payloads: Harnessing the Immune System for ADC Therapy
  • Using ADCs to deliver immune-activating molecules directly to tumors
  • Payloads designed to stimulate T cells, NK cells, or macrophages in the tumor microenvironment
  • Combination strategies with immune checkpoint inhibitors to enhance anti-tumor responses
12:30
Lunch – Exhibition Viewing & 1-1 Networking
2:15
Advancing Clinical Progress of Next-Generation ADC Pipelines in East Asia
  • Sharing latest clinical trial updates and milestones from ongoing ADC programmes in East Asia
  • Highlighting early efficacy, safety, and translational data across solid tumour and haematology indications
  • Discussing regulatory pathways and strategies to accelerate ADC approvals in Asia and global markets
2:40
The Next Wave of ADC Approvals: Key Learnings from Recent FDA and EMA Submissions
  • Clinical trial design strategies that accelerate ADC approval
  • Overcoming safety concerns: Managing off- target toxicity
  • Case studies of recent successful ADC approvals and regulatory hurdles
Reserved for Solution Provider
3:20
Translating ADC Innovation into Clinical Success Across East Asia
  • Showcasing breakthrough clinical achievements and first-in-human data from East Asian biopharma companies
  • Sharing lessons learned from ADC clinical development, manufacturing readiness, and global partnering efforts
  • Evaluating the future landscape of ADC therapeutics including dual payloads, novel targets, and next-generation conjugation platforms
3:45
Afternoon Break – Exhibition Viewing & 1-1 Networking
4:15
Purification and Analytical Strategies for High-Quality ADCs
  • Advanced purification approaches to remove aggregates and free payloads
  • Analytical methods for characterization: DAR, stability, and impurity profiling
  • Addressing scalability challenges in downstream processing
4:40
Linker Innovation: Enhancing Stability and Controlled Drug Release
  • Cleavable vs non-cleavable linkers: design considerations and trade-offs
  • Tumor-selective release mechanisms and microenvironment triggers
  • Improving plasma stability to reduce systemic toxicity
4:55
Optimizing Payload-Linker Integration for Superior ADC Performance
  • Synergizing linker and payload design to maximize therapeutic index
  • Impact of conjugation chemistry on payload delivery and efficacy
  • Translational insights from preclinical optimization to clinical outcomes
5:20
Chairman Closing Remarks
5:25
End of Conference Day 1
6:00
ABEA Awards 2027
ADC ASIA CONGRESS 2027

Day 2

Wednesday, 24 March 2027

8:50
Chairman Opening Remarks
9:00
Harnessing Predictive Analytics for Enhanced Process Monitoring in Biologics Manufacturing
  • Using predictive analytics to ensure process consistency and minimize deviations.
  • Leveraging Al and machine learning to forecast and mitigate risks in biologics production.
9:25
Streamlining Quality Control in Biologics Manufacturing: Best Practices and Emerging Technologies
  • Advanced tools for rapid and accurate quality testing of biologics.
  • Best practices for aligning quality control processes with regulatory guidelines.
  • The role of automation and digital tools in enhancing QC efficiency
Reserved for Solution Provider
10:15
Purification and Formulation Strategies for ADC Manufacturing
  • Addressing aggregation and stability challenges during ADC purification
  • Advances in chromatography techniques for high-purity ADC isolation
  • Lyophilization and storage considerations for long-term ADC stability
10:30
Morning Break – Exhibition Viewing & 1-1 Networking
11:15
Enhancing ADC Performance: Tackling Toxicity and Resistance
  • Addressing dose-limiting toxicities in clinical settings
  • Overcoming resistance through novel design approaches
  • Role of dual payloads and combination strategies
11:40
Enhancing ADC Yield and Consistency: Advances in Bioconjugation Technologies
  • Site-specific vs. random conjugation: Impact on ADC stability and efficacy
  • Al-driven process optimization for consistent drug-to-antibody ratio (DAR)
  • Novel bioconjugation chemistries to improve homogeneity
Reserved for Solution Provider
12:05
Enhancing ADC Performance: Tackling Toxicity and Resistance
  • Addressing dose-limiting toxicities in clinical settings
  • Overcoming resistance through novel design approaches
  • Role of dual payloads and combination strategies
12:30
Lunch – Exhibition Viewing & 1-1 Networking
2:10
Clinical Development Updates and Future Directions for Emerging ADC Therapies
  • Presenting Phase I–III clinical progress and pipeline expansion strategies for novel ADC candidates
  • Exploring patient selection, biomarker strategies, and combination therapy approaches in clinical studies
  • Addressing key challenges in dose optimisation, toxicity management, and clinical differentiation
2:35
Dual-Targeting and Bispecific ADCs: Enhancing Tumor Selectivity
  • Development of bispecific ADCs to improve tumor penetration
  • Addressing tumor heterogeneity with dual- antigen recognition
  • Engineering strategies to reduce off-target effects
Reserved for Solution Provider
2:50
Leadership Panel Discussion: Current Market Trends and Future Directions for ADCs
  • Expanding ADC applications beyond oncology: Autoimmune diseases and infectious diseases
  • Investment trends in ADC biotech startups and big pharma partnerships
  • Navigating global regulatory requirements: Differences in approval pathways
3:15
Afternoon Break – Exhibition Viewing & 1-1 Networking
5:20
End of Conference
CELL & GENE THERAPY WORLD ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC Opening Remarks
8:55
Chairman Welcome Remarks
Next-Generation Cell & Gene Therapies: CAR-T, Gene Editing & Emerging Modalities
9:00
Panel Discussion: Next-Generation Cell & Gene Therapies: Advancing CAR-T, Gene Editing and Emerging Therapeutic Modalities in Asia
  • How are emerging technologies such as CAR-T, gene editing, and engineered immune cell therapies shaping the next generation of CGT development in Asia?
  • What are the key scientific, manufacturing, and clinical challenges that need to be addressed to accelerate CGT translation from research to patient access?
  • How can Asia strengthen its CGT ecosystem through collaboration across biotech companies, research institutions, hospitals, and manufacturing partners?
9:45
Enabling Scalable Cell & Gene Therapy Development Through Advanced Manufacturing Solutions
  • Optimising workflows for scalable CGT production
  • Improving process control, automation, and manufacturing efficiency
  • Supporting GMP readiness from development to commercialisation
Reserved for Solution Provider
10:00
Real-World Challenges in Advancing Cell & Gene Therapies: From Clinical Development to Commercial Success
  • Lessons learned from developing and translating CGT platforms
  • Overcoming manufacturing, regulatory, and operational barriers
  • Preparing next-generation therapies for broader patient access
10:25
Morning Break, Exhibition Viewing & 1-1 Networking
From Discovery to Clinical Translation: Accelerating CGT Development
11:10
Translating Innovative Cell Therapy Platforms from Discovery to Clinical Development
  • Advancing novel CGT candidates from preclinical research into human trials
  • Addressing scientific and operational barriers during development
  • Lessons learned from early-stage clinical translation
11:35
Accelerating CGT Development Through Integrated Technologies and Innovative Workflow Solutions
  • Enabling faster transition from discovery to clinical-stage development
  • Improving efficiency through advanced analytics and automation
  • Supporting reproducible and scalable CGT workflows
Reserved for Solution Provider
11:50
Building Clinical-Ready Cell & Gene Therapies: Bridging Research, Manufacturing and Patient Delivery
  • Aligning research, CMC, and clinical strategies for successful development
  • Managing technology transfer and manufacturing readiness
  • Preparing CGT programs for regulatory milestones
12:15
Accelerating CGT Innovation in Asia: Creating Pathways from Discovery to Patient Access
  • Expanding CGT development across Asia Pacific markets
  • Building collaborations between biotech, hospitals, and research institutions
  • Overcoming regulatory and commercialisation challenges
12:40
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Gene & Cell Therapy Platforms: Vector Engineering, Delivery & Analytics
2:00
Optimising Viral Vector Platforms for Next-Generation Gene Therapies
  • Advances in viral vector design and manufacturing strategies
  • Improving potency, safety, and scalability
  • Overcoming challenges in clinical translation
2:25
Enabling Next-Generation CGT Development Through Advanced Vector, Delivery and Analytical Technologies
  • Improving vector design, optimisation, and production efficiency
  • Supporting accurate characterisation and quality assessment of CGT products
  • Accelerating development timelines through innovative technology platforms
Reserved for Solution Provider
2:40
Beyond Delivery Challenges: Building Effective and Scalable Gene Therapy Platforms
  • Emerging delivery technologies for gene and cell therapies
  • Enhancing therapeutic targeting and patient outcomes
  • Lessons from clinical development programs
3:05
Harnessing Advanced Analytics to Improve CGT Development and Manufacturing Quality
  • Role of analytics in product characterisation and release testing
  • Using data-driven approaches to improve process control
  • Supporting regulatory readiness for CGT products
3:30
Afternoon Break, Exhibition Viewing & 1-1 Networking
Smart Manufacturing & Process Development for CGTs
4:10
Scaling Cell & Gene Therapy Manufacturing: From Development Processes to Commercial Production
  • Challenges in scaling CGT manufacturing operations
  • Optimising processes for consistency and quality
  • Preparing manufacturing platforms for commercial demand
4:35
Transforming CGT Manufacturing Through Automation, Digitalisation and Process Innovation
  • Enabling smarter and more efficient CGT manufacturing workflows
  • Improving process monitoring, automation, and data integration
  • Supporting GMP readiness and scalable production
Reserved for Solution Provider
4:50
Building the Future of CGT Manufacturing: Digitalisation, Automation and Operational Excellence
  • Implementing smart manufacturing strategies for advanced therapies
  • Leveraging digital tools for process optimisation
  • Improving manufacturing agility and efficiency
5:15
End of Conference Day 1
6:00
Asia Pacific Cell & Gene Therapy Excellence Awards 2027
CELL & GENE THERAPY WORLD ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC Opening Remarks
8:55
Chairman Welcome Remarks
Advanced Cell Therapies: Beyond Traditional CAR-T
9:00
Beyond CAR-T: Advancing Next-Generation Immune Cell Therapies for Improved Patient Outcomes
  • Evolution of CAR-NK, TCR-T, and engineered immune cell platforms
  • Addressing limitations of current CAR-T approaches
  • Translating novel cell therapies into clinical applications
9:25
Enabling Next-Generation Cell Therapies Through Advanced Manufacturing and Cell Engineering Technologies
  • Supporting development of innovative cell therapy platforms beyond CAR-T
  • Improving cell engineering, automation, and manufacturing workflows
  • Enabling scalable and reproducible production for clinical applications
Reserved for Solution Provider
9:40
The Future of Cell Therapy: Harnessing iPSC, Gene Editing and Universal Cell Platforms
  • Development of off-the-shelf cell therapy approaches
  • Improving scalability and manufacturing efficiency
  • Expanding access to advanced therapies
10:05
Engineering Smarter Cell Therapies: Innovation Pathways from Research to Clinical Development
  • Advances in cell engineering technologies
  • Improving therapeutic potency and safety profiles
  • Overcoming challenges in clinical translation
10:30
Morning Break, Exhibition Viewing & 1-1 Networking
Manufacturing Excellence: Scale-Up, Tech Transfer & CMC Readiness
11:10
From Clinical Manufacturing to Commercial Scale: Building Robust CGT Production Platforms
  • Challenges in scaling cell and gene therapy manufacturing
  • Developing reliable GMP manufacturing processes
  • Preparing facilities and operations for commercial supply
11:35
Enabling Scalable CGT Manufacturing Through Advanced Process Technologies and CMC Solutions
  • Supporting efficient scale-up from development to GMP production
  • Improving process control, automation, and manufacturing consistency
  • Accelerating CMC readiness for regulatory approval
Reserved for Solution Provider
11:50
Successful Tech Transfer in CGT: Bridging Development, Manufacturing and Regulatory Requirements
  • Managing technology transfer between sites and partners
  • Maintaining product quality during process changes
  • Aligning manufacturing strategies with regulatory expectations
12:15
CMC Readiness for Next-Generation Therapies: Overcoming Manufacturing and Regulatory Challenges
  • Building CMC strategies early in CGT development
  • Addressing analytical, quality, and process challenges
  • Supporting faster progression toward market approval
12:40
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Supply Chain & Operational Excellence for CGTs
2:00
From Vein-to-Vein: Optimising Cell Therapy Supply Chains for Clinical and Commercial Success
  • Managing patient-specific therapy logistics
  • Improving coordination between collection, manufacturing, and delivery
  • Reducing operational risks across the CGT journey
2:25
Building Resilient CGT Supply Chains Through Advanced Logistics, Traceability and Digital Solutions
  • Improving end-to-end visibility across CGT supply networks
  • Ensuring product integrity through temperature-controlled logistics
  • Supporting scalable operations for personalised therapies
Reserved for Solution Provider
2:40
Scaling CGT Operations: Building Infrastructure for Global Cell Therapy Delivery
  • Developing scalable operational models for growing CGT demand
  • Managing manufacturing capacity and supply continuity
  • Preparing for commercial deployment across regions
3:05
Digital Transformation in CGT Supply Chains: Enhancing Visibility, Compliance and Efficiency
  • Using digital platforms for tracking and traceability
  • Improving data integration across CGT workflows
  • Supporting regulatory compliance and operational excellence
3:30
Afternoon Break, Exhibition Viewing & 1-1 Networking
Regulatory Pathways, Market Access & Commercialization
4:10
From Approval to Adoption: Building Successful Commercial Strategies for Cell & Gene Therapies
  • Navigating regulatory pathways for advanced therapies
  • Developing market access strategies for innovative treatments
  • Preparing CGTs for commercial launch and patient availability
4:35
Commercialising Cell & Gene Therapies: Overcoming Regulatory and Healthcare System Challenges
  • Managing regulatory requirements across global markets
  • Addressing reimbursement and healthcare adoption barriers
  • Creating sustainable commercial models for CGT delivery
5:00
The Future of CGT in Asia: Building Regulatory Alignment and Expanding Patient Access
  • Regulatory evolution across Asia Pacific markets
  • Opportunities for regional CGT collaboration
  • Accelerating access to advanced therapies for patients
5:25
Chairman Closing Remarks
5:30
End of Conference
CLINICAL TRIALS FESTIVAL ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC Representative
8:55
Chairperson Opening Remarks:
APAC Trial Harmonization & Emerging Markets: Multi-country Trial Design and Next-wave Market Spotlight
9:00
One Region, Many Rules: Designing Multi-Country Trials Across APAC's Regulatory Patchwork
  • How regulatory convergence initiatives (and their limits) are shaping multi-country trial strategy today
  • Practical strategies for harmonizing trial protocols, data standards, and ethics submissions across multiple countries
  • Spotlight on next-wave markets and what sponsors need to know before expanding trials into them
  • Lessons learned from early movers on de-risking multi-country trial design in emerging markets
9:50
One Region, Infinite Complexity: Reimagining Clinical Development Across APAC
  • A big-picture reflection on the opportunities and risks of scaling clinical trials across APAC's diverse markets
  • What true regulatory and operational harmonization would mean for sponsors, sites, and patients alike
  • A call to action on how the industry can collectively unlock next-wave markets faster and more responsibly
Reserved for Technology/Solution Provider
10:15
The Future of Clinical Trials in APAC: Harmonization, Access, and the Next Wave of Markets
  • A region-wide perspective on where APAC clinical trial harmonization stands today, and where it needs to go
  • Why multi-country trial design is becoming a strategic imperative, not just an operational challenge
  • A forward-looking view on which emerging markets will define the next decade of trial activity in APAC
Naveen Jain
Naveen Jain
VP, Pre-Clinical, Panacea Biotec
10:40
MORNING TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Navigating the Future of Patient-Centric Trials: Recruitment, Retention, and Patient Diversity
11:15
Cracking the Code on Patient Recruitment: Strategies to Beat Enrollment Bottlenecks in APAC
  • How to identify and overcome region-specific barriers to patient enrollment across diverse APAC healthcare systems
  • Site selection and feasibility strategies that speed up recruitment timelines without compromising data quality
  • Using digital outreach and community partnerships to widen the recruitment funnel in underserved markets
11:40
Beyond Enrollment: Building Retention and Diversity into Trial Design
  • Designing protocols that reduce patient burden and minimize dropout across long-duration, complex studies
  • Practical approaches to embedding ethnic, geographic, and socioeconomic diversity into trial populations from the outset
  • Case studies on retention strategies that worked (and didn't) in multi-country APAC trials
Reserved for Technology/Solution Provider
12:05
The Patient-Centric Trial: Decentralized Models, Digital Tools, and Inclusive Access
  • How decentralized trial elements (telehealth, remote monitoring, e-consent) are reshaping patient experience in APAC
  • Balancing technology adoption with accessibility for patients across varying digital literacy and infrastructure levels
  • Measuring the real impact of patient-centric design on recruitment speed, retention, and data diversity
Reserved for Technology/Solution Provider
12:20
Rethinking Trial Access: Recruitment and Retention Models for a More Inclusive APAC
  • Addressing structural and cultural barriers that limit patient access to clinical trials across APAC's varied healthcare landscapes
  • Site and investigator engagement strategies that build trust and sustain patient participation through trial completion
  • Frameworks for setting and measuring diversity targets that reflect real APAC disease burden and population demographics
12:35
LUNCH, EXHIBITION VIEWING, 1-1 NETWORKING
Advancing Pre-Clinical Research Bringing the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
2:15
Advancing Clinical Progress of Next-Generation ADC Pipelines in East Asia
  • Sharing latest clinical trial updates and milestones from ongoing ADC programmes in East Asia
  • Highlighting early efficacy, safety, and translational data across solid tumour and haematology indications
  • Discussing regulatory pathways and strategies to accelerate ADC approvals in Asia and global markets
2:40
The Next Wave of ADC Approvals: Key Learnings from Recent FDA and EMA Submissions
  • Clinical trial design strategies that accelerate ADC approval
  • Overcoming safety concerns: Managing off- target toxicity
  • Case studies of recent successful ADC approvals and regulatory hurdles
Reserved for Solution Provider
3:05
Translating ADC Innovation into Clinical Success Across East Asia
  • Showcasing breakthrough clinical achievements and first-in-human data from East Asian biopharma companies
  • Sharing lessons learned from ADC clinical development, manufacturing readiness, and global partnering efforts
  • Evaluating the future landscape of ADC therapeutics including dual payloads, novel targets, and next-generation conjugation platforms
3:45
AFTERNOON TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Decentralized Trials, Digital Endpoints, and Wearables
4:15
Decentralized Trials in Practice: Scaling Digital Endpoints and Wearables Across APAC
  • Practical frameworks for implementing DCT models across APAC's varied regulatory and infrastructure landscapes
  • Validating digital endpoints and wearable-derived data for regulatory acceptance and clinical decision-making
  • Case studies on hybrid and fully decentralized trials that improved data quality and patient convenience
4:40
From Pilot to Standard: The Maturing Role of Wearables and Digital Endpoints in Clinical Trials
  • How wearables and sensor-based endpoints are moving from exploratory tools to primary and secondary trial measures
  • Overcoming data integration, standardization, and interoperability challenges across devices and platforms
  • Regulatory perspectives on qualifying digital endpoints for use in pivotal APAC and global trials
5:05
Building Trust in Decentralized Data: Technology, Compliance, and Patient Experience
  • Ensuring data integrity, privacy, and compliance when deploying remote monitoring and digital tools across APAC markets
  • Balancing sponsor technology ambitions with site and patient readiness for decentralized trial components
  • What sponsors need to know about local regulatory guidance on DCT and digital endpoint adoption in APAC
5:30
END OF CONFERENCE DAY 1
6:00
CLINICAL TRIALS EXCELLENCE AWARDS 2027
CLINICAL TRIALS FESTIVAL ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC Representative
8:55
Chairperson Opening Remarks:
AI & Digital Transformation in Trial Execution: AI in Feasibility, eSource, Protocol Design
9:00
The AI-Ready Trial: Rethinking Feasibility, Data Capture, and Protocol Design for Speed
  • What sponsors need to build AI capability into feasibility planning and site selection processes
  • Overcoming adoption barriers to AI-enabled eSource across APAC sites with varying digital maturity
  • How AI and predictive analytics are being used to design smarter, more efficient trial protocols from the outset
9:25
Smarter Trials by Design: AI's Expanding Role in Feasibility and Protocol Optimization
  • How AI is helping sponsors move from reactive to predictive feasibility planning
  • Reducing protocol amendments by using AI to stress-test trial design before activation
  • What "AI-ready" eSource infrastructure looks like, and the gaps still holding APAC sites back
Reserved for Solution Provider
9:55
Agentic and AI Transformation of Preclinical Data Analysis (tbc)
  • Why real-time eSource data capture is becoming a competitive necessity, not a nice-to-have
  • How AI is being layered onto existing data systems to flag risks and inefficiencies earlier
  • Balancing innovation speed with data integrity and regulatory expectations across APAC markets
Matthew Choo, Ph.D.
Matthew Choo, Ph.D.
Associate Director, Data Science, MSD
10:20
MORNING TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Transforming Clinical Trial Logistics in APAC [Presentations at BSCA Room]
11:10
Engineering the Next Generation of Biopharma Manufacturing: Building Scalable, Smart & Resilient Facilities
  • Connecting planning, manufacturing and logistics through integrated digital platforms
  • Using real-time data and predictive intelligence to improve end-to-end decision-making
  • Automating workflows and reducing operational complexity across the supply chain
  • Building scalable digital capabilities that strengthen resilience, agility and performance
Maneesh Ghildyal
Maneesh Ghildyal
VP & Global Head, Projects & Engineering, Biocon Biologics
11:35
Optimising Decentralised Clinical Trials Through Connected Logistics Technologies
  • Enabling direct-to-patient and site-to-patient deliveries
  • Real-time shipment visibility through connected monitoring platforms
  • Reducing risk with predictive temperature and lane analytics
  • Supporting patient-centric clinical trials with integrated logistics solutions
Reserved for Solution Provider
12:05
Transforming Clinical Trial Supply Chains for Faster & Smarter Research
  • Demand forecasting and inventory strategies
  • Enhancing visibility and coordination across sponsors, depots, and logistics partners
  • Digital technologies to improve trial supply agility while maintaining regulatory compliance
12:30
LUNCH, EXHIBITION VIEWING, 101 NETWORKING1
APAC CRO Showcase: From Early-Phase to Late-Stage: Showcasing End-to-End Clinical Research Capabilities
2:15
The Access Equation: Connecting Clinical Evidence to Market Realities in APAC
  • Turning post-authorization and real-world data into evidence that supports pricing and reimbursement decisions
  • The expanding role of medical affairs in shaping payer conversations and health technology assessments
  • Country-specific market access hurdles across APAC and how sponsors are adapting their approach
2:40
Building Seamless Clinical Development Pathways
  • The strategic advantages of consistent data, teams, and infrastructure across the entire trial lifecycle
  • How early-phase insights can directly inform and de-risk late-stage trial design and execution
  • Showcasing real-world examples of end-to-end clinical research driving faster, more efficient program delivery
3:05
After the Approval: Making Post-Authorization Data Work Harder for Market Access
  • Using post-authorization commitments as a strategic tool for generating real-world evidence, not just a regulatory obligation
  • How medical affairs functions are being restructured to support faster, more coordinated payer engagement
  • Practical approaches to closing the gap between approval and actual patient access across APAC markets
3:20
AFTERNOON TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Closing Panel Discussion: Rethinking Clinical Development as a Continuous Journey
4:15
Panel Discussion: One Partner, Every Phase: Rethinking Clinical Development as a Continuous Journey
  • Why continuity from early-phase discovery through late-stage execution is becoming a competitive differentiator in APAC
  • Breaking down the operational and data silos that typically separate early and late-phase trial work
  • How end-to-end capabilities support faster, more informed go/no-go decisions across the development timeline
5:00
END OF CONFERENCE DAY 2
OLIGOS & PEPTIDES WORLD ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
RNA & Oligonucleotides Landscape in APAC
9:00
Leadership Panel: Scaling Asia's Leadership in Oligonucleotide & Peptide Therapeutics
  • What will position APAC as the next global hub for oligonucleotide and peptide therapeutics?
  • How can industry accelerate commercialization while strengthening regional manufacturing capacity?
  • Which partnerships are critical to build a globally competitive innovation ecosystem?
9:50
Scaling Manufacturing for Oligonucleotide–Peptide Conjugates
  • Scaling synthesis and conjugation processes
  • Ensuring manufacturing consistency
  • Overcoming production challenges
  • Building scalable pathways for clinical supply
Reserved for Solution Provider
10:05
Building Asia-Based RNA Development & Manufacturing Ecosystems
  • Strengthening regional capabilities from discovery through GMP manufacturing
  • Reducing dependency on fragmented global development networks
  • Accelerating technology transfer and capability building across APAC
  • Creating integrated pathways from research to commercial supply
10:30
Morning Tea, Exhibition Viewing & 1-1 Networking
Peptide Therapeutics 2.0: Beyond Metabolic Diseases
11:15
High-Throughput Peptide Screening for Oncology, Immunology & Rare Diseases
  • Building screening strategies for complex disease targets
  • Identifying functional hits from diverse peptide libraries
  • Evaluating potency, selectivity and stability early
  • Prioritising candidates for further development
11:40
From Peptide Hit to Drug Candidate: Optimising Stability, Selectivity & Developability
  • Improving peptide stability and half-life
  • Optimising selectivity and target engagement
  • Addressing developability challenges early
  • Supporting efficient progression from hit discovery to candidate selection
Reserved for Solution Provider
11:55
Beyond GLP-1: The Next Wave of Peptide Therapeutics
  • Expanding peptides into oncology, immunology, neurological and rare diseases
  • Targeting undruggable and intracellular targets
  • Advancing multi-agonist and multispecific peptide platforms
  • Differentiating peptides from antibodies and small molecules
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Delivery Technologies & Precision Tissue Targeting
2:05
Panel Discussion
The Next Frontier in Precision Delivery for Oligonucleotide Therapeutics
Questions:
  • Which delivery technologies show the strongest potential for extrahepatic oligonucleotide delivery?
  • How are companies tackling delivery to difficult tissues including CNS, muscle and immune cells?
  • What approaches are emerging to overcome endosomal escape and improve intracellular activity?
  • What will it take to move next-generation delivery platforms from promising preclinical data into clinical development?
2:35
Breaking Biological Barriers: Next-Generation Delivery for Tissue-Targeted Peptide Therapeutics
  • Engineering peptides to overcome membrane, epithelial and physiological barriers that restrict tissue exposure.
  • Advancing receptor-mediated and ligand-directed strategies for cell- and tissue-specific uptake.
  • Optimising biodistribution while reducing off-target exposure and systemic toxicity.
  • Translating delivery performance from preclinical models into clinically relevant tissue exposure and efficacy.
Reserved for Solution Provider
2:50
Beyond the Injection: Engineering Oral & Non-Invasive Delivery for Peptide Therapeutics
  • Overcoming enzymatic degradation, poor permeability and low bioavailability across oral and mucosal routes.
  • Evaluating permeation enhancers, nanoparticles, lipid systems and other formulation technologies.
  • Connecting peptide molecular design with route-of-administration and formulation strategy.
  • Closing the gap between promising bioavailability data and scalable, patient-friendly products.
3:25
Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Networking
Oligonucleotide-Peptide Conjugates & Novel Modalities
4:10
Panel Discussion: Beyond GalNAc: Peptide-Oligonucleotide Conjugates for the Next Frontier of Targeted Delivery
  • Breaking the liver barrier: enabling extrahepatic delivery to muscle, CNS and other difficult-to-reach tissue
  • Engineering peptide ligands for greater cell and tissue specificity, uptake and intracellular trafficking
  • Optimising linker chemistry, conjugation architecture and oligonucleotide design for stability and potency
  • Translating promising delivery platforms into clinically viable and scalable therapeutics
4:40
Conjugate by Design: Engineering the Next Generation of Peptide-Oligonucleotide Therapeutics
  • Designing the optimal peptide–linker–oligonucleotide architecture for therapeutic performance
  • Balancing potency, selectivity, stability, PK/PD and intracellular release
  • Comparing cell-penetrating, receptor-targeting and tissue-specific peptide strategies
  • Applying computational and AI-enabled approaches to accelerate conjugate design and candidate selection
Reserved for Solution Provider
4:55
Conjugates at Scale: Manufacturing the Next Generation of Oligonucleotide–Peptide Therapeutics
  • Scaling synthesis and conjugation while maintaining yield, purity and batch consistency
  • Tackling purification challenges associated with conjugated and non-canonical molecules
  • Controlling critical quality attributes, impurities and conjugation-related heterogeneity
  • Building scalable and commercially viable CMC strategies from clinical development onward
5:20
Chairman’s Closing Remarks
5:30
End of day 1 conference
6:00
Cocktails & Networking
6:30
Asia-Pacific Biopharma Excellence Awards 2027 Gala Dinner
OLIGOS & PEPTIDES WORLD ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
Clinical Development & Regulatory Excellence
9:00
FDA & EMA Regulatory Readiness for Oligonucleotide & Peptide Therapeutics: From Early Development to Global Approval
  • Navigating regulatory expectations for novel oligonucleotide and peptide modalities
  • Designing clinical development strategies that support regulatory decision-making
  • Addressing evidence requirements for novel mechanisms and emerging modalities
  • Building regulatory strategies across the U.S., Europe and APAC
9:25
From First-in-Human to Approval: De-Risking Clinical Development for Oligos & Peptides
  • Designing efficient FIH and early-phase trials for novel oligonucleotide and peptide modalities.
  • Translating preclinical PK/PD, biodistribution and toxicology into dose selection and escalation strategies.
  • Identifying meaningful biomarkers and clinical endpoints to demonstrate early proof of mechanism and efficacy.
  • Building regulatory evidence packages that support faster progression from Phase I through pivotal development.
Reserved for Solution Provider
9:40
Dose Matters: Optimising Exposure, Target Engagement & Therapeutic Window in Oligo and Peptide Trials
  • Translating tissue exposure and target engagement into rational clinical dose selection.
  • Applying PK/PD modelling to understand dose-response relationships and therapeutic windows.
  • Managing prolonged pharmacological effects and complex dosing intervals in oligonucleotide programmes.
  • Integrating emerging clinical data to optimise dose and regimen ahead of pivotal development.
10:05
From Accelerated Approval to Global Launch: Late-Stage Development & Lifecycle Strategy for Oligos and Peptides
  • Designing pivotal programmes around meaningful clinical endpoints and regulatory expectations.
  • Establishing confirmatory evidence strategies for accelerated or conditional approval pathways.
  • Integrating clinical, CMC and regulatory readiness as programmes move toward commercialisation.
  • Planning post-marketing commitments, real-world evidence and lifecycle expansion into new indications.
10:30
Morning Break, Exhibition Viewing & 1-1 Networking
Manufacturing, CMC & Commercial Scale-Up
11:15
Tech Transfer Without the Turbulence: Moving Oligo & Peptide Processes into GMP Manufacturing
  • Defining the critical process and analytical knowledge required for successful technology transfer
  • Bridging gaps between process development, analytical, manufacturing, quality and external CDMO teams
  • Establishing comparability when processes, equipment or manufacturing sites change
  • Using risk-based transfer strategies to shorten timelines while protecting product quality and supply
11:40
Scaling the Chemistry: Optimising SPPS & Oligonucleotide Synthesis for Cost, Yield and Throughput
  • Overcoming scale limitations in solid-phase peptide and oligonucleotide synthesis
  • Optimising coupling efficiency, reagent consumption, cycle times and resin/support utilisation
  • Reducing solvent intensity, waste generation and cost of goods at commercial volumes
  • Evaluating where liquid-phase, hybrid and alternative synthesis technologies can outperform conventional approaches
Reserved for Solution Provider
11:55
Breaking the Solid-Phase Ceiling: Enzymatic, Hybrid & Next-Generation Manufacturing for Oligos and Peptides
  • Assessing where enzymatic and hybrid synthesis can overcome conventional solid-phase limitations
  • Comparing scalability, selectivity, productivity, cost and environmental footprint
  • Addressing new CMC and regulatory considerations introduced by alternative manufacturing technologies
  • Defining what is required to transition emerging synthesis platforms from proof-of-concept to GMP and commercial production
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Quality, Analytics & Regulatory Innovation
2:05
From Development to GMP: Building Phase-Appropriate Analytical Control Strategies That Scale
  • Designing analytical methods early with commercial scalability and GMP readiness in mind
  • Defining CQAs and translating them into robust release and in-process controls
  • Moving methods from development laboratories into QC without losing robustness
  • Aligning analytical development, process development, QC and CMC teams to reduce late-stage surprises
2:30
AI-Powered Analytical Development: Can Automation Accelerate Release of Complex Therapeutics?
  • Applying AI and machine learning to analytical data interpretation
  • Automating data review while maintaining human oversight
  • Strengthening data integrity and traceability
  • Moving toward faster, risk-based QC and batch release
Reserved for Solution Provider
2:45
Beyond the Main Peak: Advanced Impurity Profiling & Control Strategies for Oligos and Peptides
  • Identifying process-, product- and degradation-related impurities across increasingly complex molecules
  • Applying LC-MS/HRMS and orthogonal analytical techniques to resolve closely related species
  • Linking impurity origin and formation pathways to CQAs and process controls
  • Establishing scientifically justified impurity thresholds and specifications for regulatory submissions
3:10
Analytics for the Next Generation: Characterising Conjugated, Modified & Non-Canonical Oligos and Peptides
  • Tackling heterogeneity introduced by conjugation, chemical modifications and novel structures
  • Combining chromatographic, mass spectrometric and orthogonal methods for deeper characterization
  • Defining molecule-specific CQAs for increasingly complex modalities
  • Developing platform analytical approaches while retaining flexibility for modality-specific risks
3:35
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Convergence of RNA, Peptides & Next-Generation Therapeutics
4:20
Beyond ADCs: APCs & RDCs for the Next Wave of Precision Therapeutics
  • Advancing APCs and RDCs as emerging targeted therapeutic platforms
  • Expanding applications beyond traditional oncology
  • Optimising targeting, payload design and therapeutic precision
  • Translating novel conjugates from platform innovation to the clinic
4:25
From Breakthrough Platform to Global Product: What Will It Take to Commercialize Next-Generation Therapeutics?
  • Identifying technologies with the strongest potential to reach commercial scale
  • Overcoming delivery, CMC, regulatory and market-access barriers
  • Building global development and manufacturing strategies from Asia
  • Turning platform innovation into sustainable product pipelines
Reserved for Solution Provider
4:40
AI-Enabled mRNA Therapeutics: From Precision Design to Clinical Translation
  • Applying AI and in silico approaches to optimise therapeutic mRNA design
  • Integrating computational prediction with biological and immunological validation
  • Advancing precision mRNA approaches for therapeutic applications
  • Translating next-generation mRNA platforms into clinical-stage programmes
Wonil Kim
Wonil Kim
CSO, Aston Sci
5:05
Accelerating RNA Therapeutic Discovery: High-Throughput Screening, Design & Safety
  • High-throughput screening strategies for RNA therapeutic discovery
  • Compound design and optimisation to accelerate candidate selection
  • Integrating in vitro safety assessment during early lead development
  • Improving the quality and confidence of preclinical RNA candidates
Dr. Pratik Dave
Dr. Pratik Dave
Senior Scientist, Roche
5:30
Asia’s Next Wave of RNA & Peptide Innovation - What Will Win the Race to Market?
Questions:
  • Which therapeutic modality will define the next phase of RNA and peptide innovation?
  • Where should industry focus next: delivery, clinical validation, manufacturing or regulatory strategy?
  • Can Asia become the global launchpad for next-generation therapeutics rather than simply a development and manufacturing hub?
6:15
Chairman’s Closing Remarks
6:20
End of day 2 conference
BIOSUPPLY CHAIN ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
9:00
Leadership Panel: Building Resilient & Future-Ready Biopharma Supply Chains in Asia
  • Supply network redesign under geopolitical uncertainty
  • Key capabilities for the next five years
  • Collaboration models with logistics partners for regional agility
9:45
Designing Digital Supply Chain Control Towers for End-to-End Visibility
  • End-to-end shipment visibility
  • Predictive risk monitoring across lanes
  • Integrated logistics partner platforms
  • Real-time analytics for disruption reduction
Reserved for Solution Provider
10:00
Building Agile Biopharma Supply Networks Across Asia
  • Regional manufacturing diversification
  • Supplier resilience strategies
  • Biologics inventory optimization
  • Disruption response frameworks
10:25
Morning Tea, Exhibition Viewing & 1-1 Networking
11:10
Managing Temperature-Sensitive Biologics Across Global Networks
  • Cold chain risk management
  • Lane qualification
  • Product integrity assurance
  • Last-mile delivery performance
11:35
Advancing Smart Cold Chain Monitoring with IoT and Sensors
  • Real-time temperature monitoring
  • IoT shipment visibility
  • Exception management systems
  • Remote monitoring technologies
Reserved for Solution Provider
11:50
Robotics and Automated Storage and Retrieval Systems (ASRS) in Controlled Environments
  • AGVs in qualified -20°C environments for safety and accuracy
  • High-density urban clinical distribution storage optimisation
  • WMS integration with global logistics control towers
  • Reduced picking errors for patient-specific therapies
12:15
Advancing Cold Chain Excellence for Next-Generation Biopharmaceuticals
  • End-to-end temperature-controlled logistics across Asia
  • Real-time monitoring and predictive analytics to improve cold chain performance
  • Balancing compliance, product integrity, and cost efficiency for high-value biologics
12:40
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
2:00
Decarbonising Global Biopharma Logistics Without Compromising Product Quality
  • Sustainable transport strategies
  • Scope 3 emissions reduction
  • Greener distribution networks
  • Sustainability measurement frameworks
2:25
Balancing ESG Goals with Supply Chain Performance
  • Supplier sustainability programmes
  • Sustainable procurement decisions
  • Carbon reporting expectations
  • Circular supply chain initiatives
Reserved for Service Provider
2:40
Designing Reusable Packaging Loops Across Highly Fragmented Asian Lanes
  • Return logistics for temperature-controlled containers
  • Maintenance and validation of reusable shippers
  • ROI modelling for reusable vs disposable packaging
  • Customs recognition for reusable assets
3:05
Afternoon Tea, Exhibition Viewing & 1-1 Networking
3:50
Intelligent Packaging Solutions for Next-Generation Biologics
  • Smart reusable packaging for biologics and vaccines
  • Embedded IoT sensors for real-time monitoring
  • Predictive analytics for shipment performance
  • Reduced product loss and sustainability gains
4:15
Strengthening Global Traceability Across Temperature-Sensitive Supply Chains
  • End-to-end serialization strategies
  • Manufacturing-to-patient traceability
  • Anti-counterfeit data systems
  • Regulatory alignment for global compliance
Reserved for Service Provider
4:30
Digital Platforms for End-to-End Supply Chain Orchestration
  • Connected planning systems
  • Digital twins
  • AI scenario modelling
  • Supply chain automation
4:55
End of Conference Day 1
6:00
Asia-Pacific Biopharma Excellence Awards 2027 Gala Dinner
BIOSUPPLY CHAIN ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
9:00
Leadership Panel: Balancing ESG Goals with Supply Chain Performance
  • How can organizations balance sustainability goals with supply chain performance?
  • What role do procurement and supplier partnerships play in achieving ESG targets?
  • How can companies measure and reduce Scope 3 emissions across the supply chain?
  • What innovations are driving circularity and greener logistics in biopharma?
9:45
Driving Enterprise-Wide Digital Transformation Across Manufacturing and Logistics (TBC)
  • Connecting planning, manufacturing and logistics through integrated digital platforms 
  • Using real-time data and predictive intelligence to improve end-to-end decision-making  
  • Automating workflows and reducing operational complexity across the supply chain  
  • Building scalable digital capabilities that strengthen resilience, agility and performance 
Reserved for Solution Provider
10:00
Transforming Global Supply Chain Planning Through AI and Advanced Analytics
  • Predictive planning
  • Intelligent inventory optimisation
  • Data-driven operational excellence
  • Building resilient digital ecosystems
Santi Purwantini
Santi Purwantini
Planning Lead, Organon
10:25
Morning Tea, Exhibition Viewing & 1-1 Networking
11:10
Engineering the Next Generation of Biopharma Manufacturing: Building Scalable, Smart & Resilient Facilities
  • Connecting planning, manufacturing and logistics through integrated digital platforms
  • Using real-time data and predictive intelligence to improve end-to-end decision-making
  • Automating workflows and reducing operational complexity across the supply chain
  • Building scalable digital capabilities that strengthen resilience, agility and performance
Maneesh Ghildyal
Maneesh Ghildyal
VP & Global Head, Projects & Engineering, Biocon Biologics
11:35
Optimising Decentralised Clinical Trials Through Connected Logistics Technologies
  • Enabling direct-to-patient and site-to-patient deliveries
  • Real-time shipment visibility through connected monitoring platforms
  • Reducing risk with predictive temperature and lane analytics
  • Supporting patient-centric clinical trials with integrated logistics solutions
Reserved for Solution Provider
11:50
Transforming Clinical Trial Supply Chains for Faster & Smarter Research
  • Demand forecasting and inventory strategies
  • Enhancing visibility and coordination across sponsors, depots, and logistics partners
  • Digital technologies to improve trial supply agility while maintaining regulatory compliance
12:15
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
2:00
Maintaining Cold Chain Compliance Across Global Distribution Networks
  • GDP best practices
  • Cold chain qualification
  • Supplier oversight
  • Audit preparedness
2:25
Advancing Singapore as Asia's Trusted Biopharma Manufacturing Hub
  • Singapore's Manufacturing 2030 strategy
  • Building resilient biopharma supply chains
  • Public-private partnerships driving innovation
  • Future investments in advanced biomanufacturing
Reserved for Service Provider
2:40
Strengthening Global GxP Compliance Across Complex Biopharma Supply Chains
  • Building harmonised GxP quality systems across global operations
  • Strengthening supplier qualification, oversight, and risk management
  • Leveraging digital technologies to improve compliance, traceability, and inspection readiness
  • Driving continuous quality improvement while maintaining supply chain resilience
Emma Dernelley
Emma Dernelley
Senior Director, Distribution & Regional Quality APAC, BeOne Medicines
3:05
Afternoon Tea, Exhibition Viewing & 1-1 Networking
3:50
Leadership Panel: Future-Proofing Biopharma Supply Chains in Asia 2027-2030
  • What will define Asia's next-generation biopharma supply chain?
  • How can organizations accelerate AI and digital transformation without compromising quality and compliance?
  • What's the one priority supply chain leaders should focus on to stay competitive over the next five years?
4:35
Aligning Manufacturing, Supply Chain & Market Access
  • Coordinating manufacturing, supply planning, and commercial teams for successful product launches
  • Managing demand uncertainty during new product introductions
  • Ensuring supply continuity while accelerating speed to market
5:00
Chairman Closing Remarks
5:05
End of Conference

Meet the Speakers

Across all six Biopharma APAC Confex 2027 programmes

Naveen Jain
Naveen Jain
VP, Pre-Clinical
Panacea Biotec
India flag India
Maneesh Ghildyal
Maneesh Ghildyal
VP & Global Head, Projects & Engineering
Biocon Biologics
India flag India
Matthew Choo, Ph.D.
Matthew Choo, Ph.D.
Associate Director, Data Science
MSD
Singapore flag Singapore
Wonil Kim
Wonil Kim
CSO
Aston Sci
South Korea flag South Korea
Dr. Pratik Dave
Dr. Pratik Dave
Senior Scientist
Roche
Switzerland flag Switzerland
Young Jun Seo
Young Jun Seo
CEO
Elonova
South Korea flag South Korea
Teck Chung Chang
Teck Chung Chang
VP, Site Quality Head
Takeda
Singapore flag Singapore
Prasad Deshpande
Prasad Deshpande
President & CTO (Technical Operations)
Shalina Healthcare
India flag India
Indira Singampalli
Indira Singampalli
VP, Head Strategic Procurement
Dr. Reddy's Laboratories
Singapore flag Singapore
Emma Dernelley
Emma Dernelley
Senior Director, Distribution & Regional Quality APAC
BeOne Medicines
Australia flag Australia
Santi Purwantini
Santi Purwantini
Planning Lead
Organon
Indonesia flag Indonesia

Awards & Recognition

Asia-Pacific Biopharma Excellence Awards 2027
23rd March 2027 | Sands Expo & Convention Centre, Singapore
The Asia-Pacific Biopharma Excellence Awards (ABEA) 2027 aims to honour exceptional achievements in the Asian biopharma sector, recognizing excellence in bioprocessing, logistics and supply chain management, antibody-drug conjugates (ADC), and clinical trials over the past year. Celebrating the remarkable contributions of leading biopharma professionals, organizations, and technologies, the awards spotlight trailblazing leaders and trendsetters shaping the industry's future while inspiring innovation for tomorrow’s biopharma landscape.
Learn More About Our Awards
By Profile
Asian Biopharma
45%
International Biopharma
20%
CMOs
15%
Academic & Research Institutes
10%
Technology & Service Providers
10%
By Job Title
VPs & Directors of Process Development
25%
USP & DSP Specialists & Researchers
25%
Head of Quality Assurance & Analytics
20%
Head of Manufacturing & Bioprocessing
15%
Business Development & Marketing
15%
By Geography
World Map
25%
Korea & Japan
18%
China, Taiwan & Hong Kong
25%
Singapore
20%
Indonesia, Australia, Thailand, India & Malaysia
12%
USA & Europe
25%
Korea & Japan
18%
China, Taiwan & Hong Kong
25%
Singapore
20%
Indonesia, Australia, Thailand, India & Malaysia
12%
USA & Europe

Who Should Sponsor?

BIOMANUFACTURING SOFTWARE
CELL CULTURE AND FERMENTATION
PROCESS OPTIMIZATION
CRYOPRESERVATION
HIGH-THROUGHPUT SCREENING
MICROFLUIDICS
BIOSENSOR TECHNOLOGY
GENE THERAPY TECHNOLOGY
SINGLE-USE TOOLS
DRUG DELIVERY
BIOPROCESSING EQUIPMENT
CELL LINE DEVELOPMENT
NEXT-GENERATION SEQUENCING
BIOINFORMATICS & COMPUTATIONAL MODELLING
AUTOMATION AND ROBOTICS
3D BIOPRINTING
GENE EDITING
CONTINUOUS MANUFACTURING
LINKER & PAYLOAD DEVELOPMENT
PROCESS DEVELOPMENT & CDMOS
FORMULATION DEVELOPMENT
BIOCONJUGATION CHEMISTRY
REGULATORY SUPPORT
PRE-CLINICAL DEVELOPMENT & CLINICAL TRIAL SUPPLY & MANAGEMENT & CROS
FILL-FINISH PACKAGING
CDMOS, CROS & ADC SERVICE PROVIDERS
ANALYTICAL TESTING & QUALITY CONTROL
CONTRACT RESEARCH ORGANIZATIONS
DIAGNOSTICS & ANALYTICAL TOOLS
LAB EQUIPMENT STERILIZATION/PURIFICATION EQUIPMENT
LOGISTICS SERVICE PROVIDERS
ENGINEERING/FACILITY/DESIGN
INTERNATIONAL CMOS
CELL-LINES, CELL CULTURE MEDIA/LAB EQUIPMENT
COLD CHAIN
ECLINICAL PLATFORMS
MEDICAL IMAGING
CLINICAL TRIALS COMPANIES
CLINICAL DATA MANAGEMENT
MEDICAL MONITORING & BIOSTATISTICS
BIOMARKERS
LAB DESIGN
SAFETY DATA REVIEW
AIRLINES & CONSULTANTS
ACTIVE PACKAGING
PASSIVE PACKAGING
WAREHOUSE & STORAGE PROVIDERS
DRUG DISTRIBUTORS
TEMPERATURE MONITORING SOLUTIONS
3PLS
LOGISTICS AUTOMATION & ROBOTICS
AI & DIGITALIZATION
COLD CHAIN EQUIPMENT
FREIGHT FORWARDERS
SHIPPING COMPANIES
PROCUREMENT SOLUTIONS
SCM MANAGEMENT
TRACKING SOLUTIONS
COMPLIANCE SOLUTION
ULTRA COLD CHAIN
SPONSORSHIP BENEFITS

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases across the six Confex programmes.

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Our Past Partners

Sartorius Logo
Becton_Dickinson_logo.svg
IDBS_Logo
WuXi Biologics
Merck
solventum-logo-horz-clr-pos-rgb
Pfanstiehl-hd
DYE logo blue 1
Aurigene
lonza
cytiva-logo-vector
avantor-inc-logo-vector
Charles_River_Laboratories_Logo.svg
Truking logo 1
cellist-1
watson-marlow (1)
Aber
Single Use Support
PharmNXT Logo_COLOUR_transparent 2K
Tosoh Bioscience
Emerson_Electric_Company
Dr Paul Lohman
Genscript GS_Logo_Primary_RGB
Acro Biosystems
Shimadzu 1
Tofflon
Jiuzhou
IKA_Logo
Gerresheimer 2
Imalife
Lisure Science
Ellab_Logo_tagline_CYAN 2_page-0001
airdynamics
unither-pharma
ATUM_RGB_Black 1
Sanisure
SHENTEK logo
Duoning-Logo-EN-small-1
Evonik
Biomed Logo (Dark Blue & Light Blue) (1) (1)
novo-nordisk
SGS_Logo.svg
Sphere Bio-use this Dark Green WSTB Primary@300x-8 1
Biohaus Media (Media Partner) Logo
BioPharma Asia Logo
Agilent-Logo-Site
Refeyn-01
SCHOTT AG
Wuxi XDC_logo_4C
LabCorp_logo
Huida Biotech
Asymbio
Asymchem_Logo
sigma-aldrich
BSP logo 1
Akesa-Logo-1
Almac Group
austrade-logo
Australian-High-Commission
Catalent-Pharma Services-TM-Logo-Color-RGB 2
Clarivate_Logo
deep-intelligent-pharma
equilab_international_logo 1
fenix-white-plate
HMRILogo_rgb_wide
ICON
Investment-NSW-WEB_2099d4f6c3
IQVIA Biotech Logo Teal 1
komtur (1)
Nucleus Network.-1
Shanhu
Southern Star Research
SRM
the DPO centre ltd
University of Newcastle
world courier logo
Cold Chain T_Logo_With_Tagline_color
peli_logo_full_color
MarkenLogo_use this_UPSHC-PL_FULL-COLOR_RGB (5) 2
Tower Cold Chain
db schenker
doubleday acquisitions
Emballiso
abu dhabi ports
Turkish_Airlines_logo
envirotainer logo
ups-asia-group
the royale international
CRYOPDP-Logo-LHS-RGB (3) (1) (1) (1)
Biocair
Fedex-logo
Intelius
phse logo
Etihad-Airways-Logo
Beijing CIMC
Time_matters_logo
bluecrux
lufthansa cargo
Qickstat
DHL_Global_Forwarding
GCCS
Willog
and many more...
PARTNER WITH US

Sponsorship Packages

Tailored sponsorship opportunities designed to maximize your brand visibility and lead generation.

Platinum Sponsor
Enquire Platinum

Branding

  • 1 Priority positioning of corporate logo as "Platinum Sponsor" on the front page of the Official Conference Brochure distributed to more than 20,000 carefully targeted senior executives
  • 1 Priority positioning of corporate logo as "Platinum Sponsor" on event web page with hyperlink to and from your website.
  • 1 Corporate profile (max 200 words) to appear within the Official event webpage
  • 1 Priority positioning of corporate logo as "Platinum Sponsor" on each event ad placed in the event's media partner's publications and on Imapac's marketing campaign including social Media activity.
  • 1 Brochure Distribution at the Registration Desk/Conference Table
  • 1 Distribution of corporate gifts (optional)

Onsite Benefits

  • 1 Pre-Conference Workshop (Half day) including room rental and 1 refreshment for 30 pax (limited to 1-2 Sponsors)
  • 1 20 mins presentation with 5 mins live Q&A to be presented during the main conference session
  • 1 Complimentary 20 mins end-user client case study presentation with 5 mins live Q&A to be presented during the main conference session
  • 1 Chairmanship on Conference Day 2 (optional and subject to availability)
  • 1 12sqm (6mx2m) Table Top Exhibition at Exhibition Hall (complimentary upgrade to 18sqm)
  • 1 Speaker Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 7 Conference Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 2 Exhibitor Pass to man the booth in the Exhibition Hall
  • 1 In-depth post-event report exclusively available to sponsors

Engagement Benefits

  • 1 Pre-event Speaker Interview to be shared with Biopharma APAC Confex community & social media activities
  • 5 Assistance in setting up 1:1 meeting with targeted companies onsite
Gold Sponsor
Enquire Gold

Branding

  • 1 Priority positioning of corporate logo as "Gold Sponsor" on the front page of the Official Conference Brochure distributed to more than 20,000 carefully targeted senior executives
  • 1 Priority positioning of corporate logo as "Gold Sponsor" on event web page with hyperlink to and from your website.
  • 1 Corporate profile (max 150 words) to appear within the Official event webpage
  • 1 Priority positioning of corporate logo as "Gold Sponsor" on each event ad placed in the event's media partner's publications and on Imapac's marketing campaign including social Media activity.
  • 1 Priority positioning of corporate logo as "Gold Sponsor" on conference backdrop, on-site signage, event banners and etc
  • 1 Brochure Distribution at the Registration Desk/Conference Table
  • 1 Distribution of corporate gifts (optional)

Onsite Benefits

  • 1 20 mins presentation with 5 mins live Q&A to be presented during the main conference session
  • 1 Complimentary Moderator role at panel / roundtable
  • 1 9sqm (4.5x2m) Table Top Exhibition at Exhibition Hall (complimentary upgrade to 12sqm)
  • 1 Speaker Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 6 Conference Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 2 Exhibitor Pass to man the booth in the Exhibition Hall
  • 1 In-depth post-event report exclusively available to sponsors

Engagement Benefits

  • 1 Pre-event Speaker Interview to be shared with Biopharma APAC Confex community & social media activities
  • 5 Assistance in setting up 1:1 meeting with targeted companies onsite
Silver Sponsor (Enhanced)
Enquire Silver Enhanced

Branding

  • 1 Positioning of corporate logo as "Silver Sponsor" on the front page of the Official Conference Brochure distributed to more than 20,000 carefully targeted senior executives
  • 1 Positioning of corporate logo as "Silver Sponsor" on event web page with hyperlink to and from your website.
  • 1 Corporate profile (max 100 words) to appear within the Official event webpage
  • 1 Positioning of corporate logo as "Silver Sponsor" on each event ad placed in the event's media partner's publications and on Imapac's marketing campaign including social Media activity.
  • 1 Positioning of corporate logo as "Silver Sponsor" on conference backdrop, on-site signage, event banners and etc

Onsite Benefits

  • 1 25 mins presentation with live Q&A to be presented during the main conference session
  • 1 6sqm (3x2m) Table Top Exhibition at Exhibition Hall (complimentary upgrade to 9sqm booth)
  • 1 Speaker Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 4 Conference Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 2 Exhibitor Pass to man the booth in the Exhibition Hall
  • 1 In-depth post-event report exclusively available to sponsors
Silver Sponsor
Enquire Silver

Branding

  • 1 Positioning of corporate logo as "Silver Sponsor" on the front page of the Official Conference Brochure distributed to more than 20,000 carefully targeted senior executives
  • 1 Positioning of corporate logo as "Silver Sponsor" on event web page with hyperlink to and from your website.
  • 1 Corporate profile (max 100 words) to appear within the Official event webpage
  • 1 Positioning of corporate logo as "Silver Sponsor" on each event ad placed in the event's media partner's publications and on Imapac's marketing campaign including social Media activity.
  • 1 Positioning of corporate logo as "Silver Sponsor" on conference backdrop, on-site signage, event banners and etc

Onsite Benefits

  • 1 15 mins presentation with live Q&A to be presented during the main conference session
  • 1 6sqm (3x2m) Table Top Exhibition at Exhibition Hall
  • 1 Speaker Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 3 Conference Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 2 Exhibitor Pass to man the booth in the Exhibition Hall
  • 1 In-depth post-event report exclusively available to sponsors
Bronze Sponsor
Enquire Bronze

Branding

  • 1 Positioning of corporate logo as "Bronze Sponsor" on the front page of the Official Conference Brochure distributed to more than 20,000 carefully targeted senior executives
  • 1 Positioning of corporate logo as "Bronze Sponsor" on event web page with hyperlink to and from your website.
  • 1 Corporate profile (max 100 words) to appear within the Official event webpage
  • 1 Positioning of corporate logo as "Bronze Sponsor" on each event ad placed in the event's media partner's publications and on Imapac's marketing campaign including social Media activity.
  • 1 Positioning of corporate logo as "Bronze Sponsor" on conference backdrop, on-site signage, event banners and etc

Onsite Benefits

  • 1 15 mins presentation with live Q&A to be presented during the main conference session
  • 1 Complimentary 1sqm space for banner display and/or small networking table at Exhibition Hall (Complimentary upgrade to 6sqm (3x2m) Table Top at Exhibition Hall for First Time Clients ONLY - one time offer)
  • 1 Speaker Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 1 Conference Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 1 In-depth post-event report exclusively available to sponsors
Exhibitor
Enquire Exhibitor

Branding

  • 1 Positioning of corporate logo as "Exhibitor" on the front page of the Official Conference Brochure distributed to more than 20,000 carefully targeted senior executives
  • 1 Positioning of corporate logo as "Exhibitor" on event web page with hyperlink to and from your website.
  • 1 Corporate profile (max 100 words) to appear within the Official event webpage
  • 1 Positioning of corporate logo as "Exhibitor" on each event ad placed in the event's media partner's publications and on Imapac's marketing campaign including social Media activity.
  • 1 Positioning of corporate logo as "Exhibitor" on conference backdrop, on-site signage, event banners and etc

Onsite Benefits

  • 1 1-2 mins promotional video to be played during the 2 days event ad slots
  • 1 6sqm (3x2m) Table Top Exhibition at Exhibition Hall
  • 2 Conference Pass to attend the premium conference sessions and network at the Exhibition Hall
  • 2 Exhibitor Pass to man the booth in the Exhibition Hall
  • 1 In-depth post-event report exclusively available to sponsors

Be a Part of This Event!

Don't miss out on unique networking, speaking and sponsorship opportunities.

Register Here!
Head of Production
Lara Santiago
+63 9176 210686
Senior Conference Producer
Melina Dass
+65 6230 3594
Conference Producer
Umairoh Nurul Hafifa
+62 856 0026 7725 | +65 6371 9704
Conference Producer
Dee Calucin
+65 6230 3595
Portfolio Specialist
Caterin Sanggita
+65 6983 6137 | +62 811654788
Business Development Manager
Ana Laxamana
+65 6983 6132
Business Development Manager
Nathan Grace Niño
+65 6983 6134 | +44 161 552 8521
Senior Networking Delegate Executive
Niti Gupta
+65 6990 1633